Form 4: Pfizer Executive Rady A. Johnson Reports Acquisition of Phantom Stock Units

Executive Vice President Rady A. Johnson reports the acquisition of phantom stock units in Pfizer through the company's Supplemental Savings Plan.

Summary

• Rady A. Johnson, an Executive Vice President at Pfizer Inc., filed a Form 4 with the SEC.
• The filing reports a transaction on September 30, 2024, where Johnson acquired 6 phantom stock units through the Pfizer Supplemental Savings Plan (SSP).
• Each unit represents one phantom share of Pfizer common stock.
• The price per share was $28.94.
• Following the transaction, Johnson directly owns 9,155 derivative securities.
• These units are settled in cash after separation from service and can be transferred into an alternative investment account at any time.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document reports a routine transaction related to executive compensation. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The acquisition of phantom stock units by an executive could be seen as a positive sign of confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding Pfizer's future performance.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the transactions of company insiders. This filing indicates an executive's participation in a company savings plan, which is a common practice.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it involves internal compensation mechanisms.

Key Dates